Is ATNM or TNYA more profitable?

Tenaya Therapeutics' return on equity of -83.75% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Tenaya Therapeutics N/A -83.75% -66.53%

Does the media refer more to ATNM or TNYA?

In the previous week, Actinium Pharmaceuticals had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 7 mentions for Actinium Pharmaceuticals and 4 mentions for Tenaya Therapeutics. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat Tenaya Therapeutics' score of 0.15 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenaya Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ATNM or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Oncobiologics N/A N/A -254.82%

Does the media refer more to ATNM or OTLK?

In the previous week, Oncobiologics had 5 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 12 mentions for Oncobiologics and 7 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat Oncobiologics' score of 0.91 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncobiologics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is CRBP or ATNM more profitable?

Corbus Pharmaceuticals' return on equity of -87.05% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -87.05% -74.22% Actinium Pharmaceuticals N/A -100.85% -47.89%

Which has preferable earnings and valuation, KZIA or ATNM?

Novogen has higher earnings, but lower revenue than Actinium Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 4,491.94 -$13.41M N/A N/A Actinium Pharmaceuticals $35.09M 1.09 -$48.82M $0.36 3.39

Is KZIA or ATNM more profitable?

Novogen's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media refer more to KZIA or ATNM?

In the previous week, Actinium Pharmaceuticals had 6 more articles in the media than Novogen. MarketBeat recorded 7 mentions for Actinium Pharmaceuticals and 1 mentions for Novogen. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat Novogen's score of 0.34 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Actinium Pharmaceuticals (ATNM) Competitors

$1.22 +0.03 (+2.52%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.23 +0.01 (+0.82%)

As of 09/18/2026 06:17 PM Eastern

Compare

ATNM vs. HUMA, TNYA, OTLK, CRBP, and KZIA

Should you buy Actinium Pharmaceuticals stock or one of its competitors? Actinium Pharmaceuticals's main competitors and comparable companies include Humacyte (HUMA), Tenaya Therapeutics (TNYA), Oncobiologics (OTLK), Corbus Pharmaceuticals (CRBP), and Novogen (KZIA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Actinium Pharmaceuticals compare to Humacyte?

Humacyte (NASDAQ:HUMA) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Humacyte has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.05, meaning that its stock price is 95% less volatile than the broader market.

Humacyte has higher earnings, but lower revenue than Actinium Pharmaceuticals. Humacyte is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.04M	79.74	-$40.83M	-$0.49	N/A
Actinium Pharmaceuticals	$35.09M	1.09	-$48.82M	$0.36	3.39

Actinium Pharmaceuticals has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Actinium Pharmaceuticals' return on equity of -100.85% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,556.29%	-983.32%	-88.84%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Humacyte currently has a consensus price target of $6.54, suggesting a potential upside of 1,017.09%. Actinium Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 309.84%. Given Humacyte's higher probable upside, research analysts clearly believe Humacyte is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 3.1% of Humacyte shares are owned by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Actinium Pharmaceuticals had 7 more articles in the media than Humacyte. MarketBeat recorded 7 mentions for Actinium Pharmaceuticals and 0 mentions for Humacyte. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat Humacyte's score of 0.67 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Positive
Actinium Pharmaceuticals	Positive

Summary

Actinium Pharmaceuticals beats Humacyte on 9 of the 16 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Tenaya Therapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Actinium Pharmaceuticals has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the broader market.

Tenaya Therapeutics' return on equity of -83.75% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Actinium Pharmaceuticals has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	1.09	-$48.82M	$0.36	3.39
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Actinium Pharmaceuticals had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 7 mentions for Actinium Pharmaceuticals and 4 mentions for Tenaya Therapeutics. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat Tenaya Therapeutics' score of 0.15 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenaya Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Actinium Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 309.84%. Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 488.84%. Given Tenaya Therapeutics' higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Actinium Pharmaceuticals beats Tenaya Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Oncobiologics?

Actinium Pharmaceuticals (NYSE:ATNM) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Actinium Pharmaceuticals has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Actinium Pharmaceuticals has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	1.09	-$48.82M	$0.36	3.39
Oncobiologics	$1.35M	117.69	-$62.42M	-$0.77	N/A

Oncobiologics' return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Oncobiologics	N/A	N/A	-254.82%

Actinium Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 309.84%. Oncobiologics has a consensus price target of $5.20, indicating a potential upside of 696.81%. Given Oncobiologics' higher probable upside, analysts plainly believe Oncobiologics is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Oncobiologics had 5 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 12 mentions for Oncobiologics and 7 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat Oncobiologics' score of 0.91 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncobiologics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oncobiologics beats Actinium Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Corbus Pharmaceuticals?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Corbus Pharmaceuticals has a beta of 2.63, meaning that its stock price is 163% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.05, meaning that its stock price is 95% less volatile than the broader market.

Corbus Pharmaceuticals' return on equity of -87.05% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

In the previous week, Corbus Pharmaceuticals had 10 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 17 mentions for Corbus Pharmaceuticals and 7 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat Corbus Pharmaceuticals' score of 0.41 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Corbus Pharmaceuticals presently has a consensus price target of $41.00, indicating a potential upside of 446.30%. Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 309.84%. Given Corbus Pharmaceuticals' higher possible upside, equities research analysts clearly believe Corbus Pharmaceuticals is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Actinium Pharmaceuticals has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A
Actinium Pharmaceuticals	$35.09M	1.09	-$48.82M	$0.36	3.39

Summary

Corbus Pharmaceuticals and Actinium Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Novogen?

Novogen (NASDAQ:KZIA) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

30.9% of Novogen shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Novogen's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Novogen currently has a consensus target price of $27.33, suggesting a potential upside of 163.07%. Actinium Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 309.84%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Actinium Pharmaceuticals had 6 more articles in the media than Novogen. MarketBeat recorded 7 mentions for Actinium Pharmaceuticals and 1 mentions for Novogen. Actinium Pharmaceuticals' average media sentiment score of 1.08 beat Novogen's score of 0.34 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novogen has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.05, suggesting that its stock price is 95% less volatile than the broader market.

Novogen has higher earnings, but lower revenue than Actinium Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	4,491.94	-$13.41M	N/A	N/A
Actinium Pharmaceuticals	$35.09M	1.09	-$48.82M	$0.36	3.39

Summary

Novogen beats Actinium Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Actinium Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATNM vs. The Competition

Export

Metric	Actinium Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$38.36M	$3.90B	$7.24B	$23.10B
Dividend Yield	N/A	3.64%	2.57%	3.62%
P/E Ratio	-0.88	14.23	274.93	28.19
Price / Sales	1.09	1,419.61	646.01	20.34
Price / Cash	N/A	108.90	76.25	36.36
Price / Book	0.93	15.45	10.46	4.67
Net Income	-$48.82M	-$22.86M	$3.49B	$1.07B
7 Day Performance	-12.86%	-1.21%	0.59%	-1.64%
1 Month Performance	7.96%	-4.42%	-2.01%	-4.25%
1 Year Performance	-23.27%	37.81%	18.09%	8.32%

Actinium Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATNM Actinium Pharmaceuticals	2.6811 of 5 stars	$1.22 +2.5%	$5.00 +309.8%	-26.1%	$38.36M	$35.09M	N/A	25	News Coverage Positive News Analyst Revision
HUMA Humacyte	3.189 of 5 stars	$0.55 -1.7%	$6.54 +1,085.9%	-67.3%	$155.85M	$2.04M	N/A	184
TNYA Tenaya Therapeutics	2.3719 of 5 stars	$0.67 -3.2%	$4.00 +496.6%	-48.5%	$155.37M	N/A	N/A	70
OTLK Oncobiologics	3.6754 of 5 stars	$0.67 +5.0%	$5.20 +676.1%	-34.1%	$155.29M	$1.35M	N/A	17	Trending News Short Interest Increase Analyst Revision Gap Up
CRBP Corbus Pharmaceuticals	3.3229 of 5 stars	$6.92 -14.4%	$41.00 +492.5%	-35.4%	$150.87M	N/A	N/A	36	News Coverage Options Volume High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ATNM) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. HUMA, TNYA, OTLK, CRBP, and KZIA

How does Actinium Pharmaceuticals compare to Humacyte?

Summary

How does Actinium Pharmaceuticals compare to Tenaya Therapeutics?

Summary

How does Actinium Pharmaceuticals compare to Oncobiologics?

Summary

How does Actinium Pharmaceuticals compare to Corbus Pharmaceuticals?

Summary

How does Actinium Pharmaceuticals compare to Novogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. HUMA, TNYA, OTLK, CRBP, and KZIA

How does Actinium Pharmaceuticals compare to Humacyte?

Which has more risk & volatility, HUMA or ATNM?

Which has higher earnings & valuation, HUMA or ATNM?

Is HUMA or ATNM more profitable?

Do analysts rate HUMA or ATNM?

Do insiders & institutionals hold more shares of HUMA or ATNM?

Does the media refer more to HUMA or ATNM?

Summary

How does Actinium Pharmaceuticals compare to Tenaya Therapeutics?

Which has more volatility & risk, ATNM or TNYA?

Is ATNM or TNYA more profitable?

Which has preferable valuation & earnings, ATNM or TNYA?

Do institutionals & insiders believe in ATNM or TNYA?

Does the media refer more to ATNM or TNYA?

Do analysts recommend ATNM or TNYA?

Summary

How does Actinium Pharmaceuticals compare to Oncobiologics?

Which has more volatility & risk, ATNM or OTLK?

Do institutionals & insiders believe in ATNM or OTLK?

Which has preferable valuation & earnings, ATNM or OTLK?

Is ATNM or OTLK more profitable?

Do analysts recommend ATNM or OTLK?

Does the media refer more to ATNM or OTLK?

Summary

How does Actinium Pharmaceuticals compare to Corbus Pharmaceuticals?

Which has more volatility & risk, CRBP or ATNM?

Is CRBP or ATNM more profitable?

Does the media prefer CRBP or ATNM?

Do insiders and institutionals have more ownership in CRBP or ATNM?

Do analysts rate CRBP or ATNM?

Which has higher earnings and valuation, CRBP or ATNM?

Summary

How does Actinium Pharmaceuticals compare to Novogen?

Do insiders and institutionals hold more shares of KZIA or ATNM?

Is KZIA or ATNM more profitable?

Do analysts recommend KZIA or ATNM?

Does the media refer more to KZIA or ATNM?

Which has more volatility & risk, KZIA or ATNM?

Which has preferable earnings and valuation, KZIA or ATNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools